Conclusions
To conclude, in this meta-regression, we found evidence to suggest that the efficacy of eptinezumab, an anti-CGRP monoclonal antibody administered by IV, is likely underestimated in ITCs that assume a common placebo effect. The contextual placebo effects inherent in current clinical trial design require further scrutiny, and alternative comparison methods (other than standard Bayesian network meta-analysis) may need to be implemented to ensure accurate and unbiased treatment comparisons.